Bio Preventive Medicine Corp. (BPM) announced that its IVD product, DNlite-DKD uPTM-FetA ELISA kit (aka DNlite-IVD103) has received registration license from Indonesian Ministry of Health. It will be the first innovative biomarker IVD product entering Indonesia market from Taiwan.
Indonesia has a total population of 270 million people, ranking fourth largest in the world. According to a report from the Indonesian MOH, the number of people with diabetes in 2021 is 19.5 million. The prevalence of diabetes is 10.6%, ranking fifth in the world. Due to various reasons, diabetes was once the fourth most deadly disease in Indonesia, second only to stroke, heart disease and cancer. According to the International Diabetes Federation (IDF), the Indonesian government's investment in diabetes-related medical expenses in 2021 reachs US$6.3 billion.
President of BPM, Dr. Karen Tseng, indicated that DNlite-IVD103 has obtained the Indonesian registration license after recently receiving market authorization from Vietnam. In addition, it has previously been approved for marketing in Malaysia and Thailand. The marketing layout of DNlite-IVD103 in Southeast Asia is perfectly in line with Taiwanese government's new southbound policy of "Leading business with medical services". BPM will continue to seek collaboration opportunities with major Taiwanese domestic hospitals, and adopt a multi-pronged strategy to seize the huge medical and health business opportunities in Southeast Asia.
Looking forward to the future, Dr. Karen Tseng said that BPM shall continue to advance the application for marketing authorization of DNlite-IVD103 for multiple indications (DKD, KT) in other regions. In markets where certification has been obtained, BPM will accelerate to build up distribution channels, and cooperate with the countries' KOLs or participate in their national plans, hoping to expand the influence of DNlite-IVD103 in DKD clinical care and treatment guidelines, and to realize the vision that DNlite becomes one of the models in global medical guidances.